Medical diagnostics company Bluejay Diagnostics Inc (stock code: BJDX) is facing financial pressure. According to the company's latest disclosed financial plan, in order to maintain normal operations and advance R&D projects, it must secure at least $20 million in additional financing before the end of fiscal year 2027.

This capital requirement highlights the common challenges faced by biotechnology companies during the commercialization of their products. Although the company has developed an innovative rapid diagnostic platform, it still needs to continuously invest funds in clinical validation, production expansion, and market development before achieving profitability. Failure to secure sufficient funding in a timely manner may affect the pace of technology transfer and its market competitiveness. Industry analysts point out that companies in the life sciences sector often require multiple rounds of financing, and the key lies in balancing R&D investment with cash flow management.